According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “
A number of other research analysts have also weighed in on the stock. Robert W. Baird initiated coverage on shares of Inflarx in a research note on Monday, January 28th. They issued an outperform rating and a $62.00 target price on the stock. ValuEngine raised shares of Inflarx from a hold rating to a buy rating in a research note on Thursday, February 28th. JPMorgan Chase & Co. raised their target price on shares of Inflarx from $42.00 to $65.00 and gave the stock a top pick rating in a research note on Tuesday, February 5th. Finally, Guggenheim initiated coverage on shares of Inflarx in a research note on Friday, February 22nd. They issued a buy rating and a $65.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $53.11.
IFRX opened at $50.56 on Thursday. Inflarx has a 1-year low of $20.31 and a 1-year high of $52.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -36.11 and a beta of -0.84.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IFRX. Bank of New York Mellon Corp purchased a new stake in shares of Inflarx during the 3rd quarter valued at approximately $277,000. Jane Street Group LLC purchased a new stake in shares of Inflarx during the 3rd quarter valued at approximately $278,000. JPMorgan Chase & Co. raised its position in shares of Inflarx by 29.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after buying an additional 2,420 shares during the period. Paloma Partners Management Co purchased a new stake in shares of Inflarx during the 4th quarter valued at approximately $526,000. Finally, Bank of America Corp DE purchased a new stake in shares of Inflarx during the 4th quarter valued at approximately $657,000. 51.01% of the stock is currently owned by institutional investors and hedge funds.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Article: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.